Welcome back everybody to another edition of “BioPharma Bitez” the top news in the industry as well as one story outside of it.
So, to kick things off, Regeneron has announced a one billion dollar upfront deal with Alnylam to use its RNA platform for their R&D projects this week.
The FDA has rejected the marketing application Zogenix submitted for its new anti-seizure medication this week. Sighting multiple issues with the clinical trial data as well as the R&D data as well.
Indivior has been indited and charge by the department of justice this week for fraud in regards to how it treated and marketed its opioid addiction treatment.
Scynexis, which is a smaller pharma company working on resistant infections announced positive patient data this week out of two patients that were treated with this new product, which treats “C-auris” which is a resistant fungal infection, which has a 30% mortality rate. Both patients survived and actually improved. So, they’re still rolling in that; there’s a lot of research going into that. And as you may have seen on the news this week, that fungal infection is actually hitting the news with quite a few cases in the U.S. right now.
And then, shareholders are finally approving the BMS-Celgene merger this week. There is a lot of fight internally and externally with the stakeholders, and they have finally decided to give the green light for that merger to go through.
So, now we are going to look outside the industry. The big news this week is the first photo ever of a black hole. So, how they did it, they took a worldwide distributed radio satellite and filmed it on two different galaxies for over a week on each. It took about two years to process all the data, some of it actually had to be printed on to actual discs and shipped to MIT to be processed by their supercomputers. Which, equated to the first ever photo of a black hole. So, they are still working to get more photos on different black holes, it is one of the first tangible signs of black hole existence and confirming scientists theories.
We are going to look at is what I am working on outside. In terms of industry, I am again, specializing in regulatory, quality, and manufacturing. So, I am happy to connect with anybody in those spaces. Even if you are not looking for a job right now, you guys are definitely in demand. So, I am happy to let you know what I am seeing out there. I am connecting with clients and candidates every day, so I can give you some market intel as well.
Feel free to share this video. I appreciate you all tuning in and I hope to see you all for another edition of “BioPharma Bitez.”